Canadian Cancer Trials Group Bulletins

General


IND.226 and IND.221 Presented at ENA and WCLC

EORTC-NCI-AACR 2016 Symposium

Two Canadian Cancer Trials Group (CCTG) Investigational New Drug (IND) trials - IND.221 and IND.226 - were recently presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

IND.221, A Dose-Ranging Study of IPH2201 (monalizumab) in Patients with Gynecologic Malignancies, was presented by the study co-chair, Dr. Anna Tinker, Medical Oncologist at the British Columbia Cancer Agency, Vancouver, during the Spotlight session.

IND.226, A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients with Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens, was presented by the study co-chair, Dr. Desiree Hao, Medical Oncologist at the Tom Baker Cancer Centre.

You can read more about the results of these studies and find links to the abstracts by using this link ... https://www.ctg.queensu.ca/news/ind-trials-presented-eortc-nci-aacr-2016-symposium
_____________________________________

IASLC 17th World Conference on Lung Cancer

Dr. Rosalyn Juergens, the co-chair of IND.226, gave an oral presentation of the experience to date on IND.226, A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients with Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens at the 17th Annual World Conference on Lung Cancer in Vienna, Austria.

You can read more about the results of this study and find a link to the abstract by using this link ... https://www.ctg.queensu.ca/news/ind226-also-presented-world-conference-lung-cancer